Tardive Dyskinesia Awareness Week – May 3-9, 2020

To report an adverse event call:


Our company

Neurocrine Biosciences is a San Diego-based biotechnology company focused on neurologic-, psychiatric-, and endocrine-related disorders. The Company’s 3 late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally acting, highly selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and valbenazine, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome. INGREZZA® (valbenazine) capsules was approved by the FDA on April 11, 2017, for the treatment of adults with tardive dyskinesia and is currently commercialized by Neurocrine in the United States.

Our website

The Neurocrine Library of Science was designed to keep you up to date on the latest scientific advances at Neurocrine. Our library doors are always open, so come back often to browse our catalog, search our database, and access important medical information related to Neurocrine products.

If you need help finding information or have any questions for us, a Neurocrine Medical Affairs professional is available to assist you and provide medical information in response to your unsolicited inquiries.

Ready to Begin?

Register to gain access to the Neurocrine Library of Science, an expansive collection of scientific resources and information.


Need to get in touch with us?

medinfo@neurocrine.com 1-877-641-3461